$130 trillion revolution in this cup?
Former Goldman Sachs executive Nomi Prins recently drank the contents of a brand-new type of battery…

To reveal why 5 billionaires are investing in this tiny $4 company behind it.

And how it could unleash a $130 trillion energy revolution.
Watch the 30-second demo here.
James E. Levine net worth and biography

James Levine Biography and Net Worth

Mr. Levine has served as Chief Financial Officer since 2021. Mr. Levine has extensive corporate and investment banking experience with both private and public biotechnology and pharmaceutical companies. Prior to joining Cardiff Oncology, Mr. Levine served as CFO of Cidara Therapeutics, where he led the financial aspects of important pre-clinical and clinical collaborations with Janssen Pharmaceuticals (part of Johnson & Johnson) and Mundipharma with a combined value of over $1.3 billion. Previously, Mr. Levine was the president and chief executive officer of Sapphire Energy Inc., a private industrial biotechnology company that was sold to two private investor groups. He also previously served in the same roles at Verenium Corp., where he negotiated six product commercialization partnerships and asset sales, before selling the company to BASF. He also previously was a managing director in the investment banking division of Goldman Sachs & Co., serving in its healthcare and energy groups.

Mr. Levine earned an MBA in finance from the Wharton School of the University of Pennsylvania and a BA in economics from Brandeis University.

What is James E. Levine's net worth?

The estimated net worth of James E. Levine is at least $92,400.00 as of September 16th, 2022. Mr. Levine owns 60,000 shares of Cardiff Oncology stock worth more than $92,400 as of October 3rd. This net worth evaluation does not reflect any other investments that Mr. Levine may own. Additionally, Mr. Levine receives a salary of $585,160.00 as CFO at Cardiff Oncology. Learn More about James E. Levine's net worth.

How old is James E. Levine?

Mr. Levine is currently 51 years old. There are 1 older executives and no younger executives at Cardiff Oncology. The oldest executive at Cardiff Oncology is Dr. Mark Erlander Ph.D., CEO & Director, who is 62 years old. Learn More on James E. Levine's age.

What is James E. Levine's salary?

As the CFO of Cardiff Oncology, Inc., Mr. Levine earns $585,160.00 per year. The highest earning executive at Cardiff Oncology is Dr. Mark Erlander Ph.D., CEO & Director, who commands a salary of $783,230.00 per year. Learn More on James E. Levine's salary.

How do I contact James E. Levine?

The corporate mailing address for Mr. Levine and other Cardiff Oncology executives is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. Cardiff Oncology can also be reached via phone at (858) 952-7570 and via email at [email protected] Learn More on James E. Levine's contact information.

Has James E. Levine been buying or selling shares of Cardiff Oncology?

James E. Levine has not been actively trading shares of Cardiff Oncology within the last three months. Most recently, on Friday, September 16th, James E. Levine bought 30,000 shares of Cardiff Oncology stock. The stock was acquired at an average cost of $1.56 per share, with a total value of $46,800.00. Following the completion of the transaction, the chief financial officer now directly owns 60,000 shares of the company's stock, valued at $93,600. Learn More on James E. Levine's trading history.

Who are Cardiff Oncology's active insiders?

Cardiff Oncology's insider roster includes John Brancaccio (Director), Mark Erlander (CEO), Vicki Kelemen (COO), James Levine (CFO), Rodney Markin (Director), and Gary Pace (Director). Learn More on Cardiff Oncology's active insiders.

Are insiders buying or selling shares of Cardiff Oncology?

In the last year, Cardiff Oncology insiders bought shares 3 times. They purchased a total of 55,000 shares worth more than $88,600.00. The most recent insider tranaction occured on September, 19th when Director Lale White bought 15,000 shares worth more than $24,600.00. Insiders at Cardiff Oncology own 3.5 % of the company. Learn More about insider trades at Cardiff Oncology.

Information on this page was last updated on 9/19/2022.

James E. Levine Insider Trading History at Cardiff Oncology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/16/2022Buy30,000$1.56$46,800.0060,000View SEC Filing Icon  
9/10/2021Buy30,000$6.47$194,100.005,000View SEC Filing Icon  
See Full Table

James E. Levine Buying and Selling Activity at Cardiff Oncology

This chart shows James E Levine's buying and selling at Cardiff Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cardiff Oncology Company Overview

Cardiff Oncology logo
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $1.56
Low: $1.52
High: $1.60

50 Day Range

MA: $2.34
Low: $1.54
High: $3.21

2 Week Range

Now: $1.56
Low: $1.13
High: $7.32

Volume

33,390 shs

Average Volume

860,126 shs

Market Capitalization

$67.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55